Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jun;41(2):61-6.
doi: 10.5152/tud.2015.65624.

Factors determining biochemical recurrence in low-risk prostate cancer patients who underwent radical prostatectomy

Affiliations

Factors determining biochemical recurrence in low-risk prostate cancer patients who underwent radical prostatectomy

Sıtkı Ün et al. Turk J Urol. 2015 Jun.

Abstract

Objective: This study was conducted to research the factors determining biochemical recurrence (BCR) in low-risk localized prostate cancer patients who underwent radical prostatectomy (RP).

Materials and methods: We retrospectively analyzed the data of 504 patients who had undergone RP between 2003 and 2013 at our clinic. One hundred and fifty-two patients who underwent RP for low-risk prostate cancer were included in the study.

Results: The mean follow-up period for patients was 58.7 (21-229) months. The mean age of the patients was 63.7±7.2 years (49-79). The mean prostate specific antigen (PSA) value was 5.25±4.22 ng/mL (3.58-9.45). The BCR rate after the operation was 25% (38/152). In the univariate analysis, recurrence determining factors were shown to include extracapsular involvement (ECI) (p=0.004), capsular invasion (CI) (p=0.001), age (p=0.014), and tumor size (p=0.006). However, only CI was found to be significant in multivariate analysis (p=0.001).

Conclusion: Capsular invasion is an independent risk factor in low-risk prostate cancer patients who underwent RP for BCR.

Keywords: Biochemical recurrence; low-risk; radical prostatectomy.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe 2004. Ann Oncol. 2005;16:481–8. - PubMed
    1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statics, 2006. CA Cancer J Clin. 2006;56:106–30. http://dx.doi.org/10.1093/annonc/mdi098. - DOI - PubMed
    1. Grossfeld GD, Chang JJ, Broering JM, Miller DP, Yu J, Flanders SC, et al. Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment: data from the CaPSURE database. J Urol. 2000;163:1171–7. http://dx.doi.org/10.3322/canjclin.56.2.106. - DOI - PubMed
    1. Zanatta DA, Andrade RJ, Pacagnan EF, München LW, Assumpção RA, Mercante VC, et al. Early stage prostate cancer: biochemical recurrenc eafter treatment. Int Braz J Urol. 2014;40:137–45. http://dx.doi.org/10.1016/S0022-5347(05)67716-6. - DOI - PubMed
    1. Boccon-Gibod L, Djavan WB, Hammerer P, Hoeltl W, Kattan MW, Prayer-Galetti T, et al. Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract. 2004;58:382–90. http://dx.doi.org/10.1590/S1677-5538.IBJU.2014.02.02. - DOI - PubMed

LinkOut - more resources